BIVI
BioVie Inc.
Price Chart
Latest Quote
$1.79
+0.01 (+0.56%)
Current Price
| Previous Close | $1.78 |
| Open | $1.80 |
| Day High | $1.86 |
| Day Low | $1.73 |
| Volume | 157,730 |
Stock Information
| Shares Outstanding | 7.54M |
| Total Debt | $296K |
| Cash Equivalents | $13.10M |
| Net Income | $-19.96M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $13.50M |
| EPS (TTM) | $-3.79 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $621K |
| Income | $-19.96M |
| Book/sh | $2.07 |
| Cash/sh | $1.74 |
| Employees | 13 |
Financial Ratios
| Quick Ratio | 9.02 |
| Current Ratio | 9.97 |
| Debt/Eq | 1.90 |
Returns & Margins
| ROA | -61.04% |
| ROE | -106.43% |
Ownership
| Insider Ownership | 0.36% |
| Institutional Ownership | 13.94% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.41 |
| P/B | 0.87 |
Analyst Data
| Recommendation | none |
| Target Price | $5.00 |
Technical Indicators
| SMA20 | $1.59 |
| SMA50 | $1.53 |
| SMA200 | $1.51 |
| RSI | 70.11 |
| ATR | 0.1519 |
| Shares Float | 7.50M |
| Short Float | 2.51% |
| Short Ratio | 1.87 |
| Volatility | 0.65 |
| Rel Volume | 1.36 |
Performance History
| Week | +9.82% |
| Month | +31.62% |
| Quarter | +26.95% |
| 6 Months | +25.17% |
| YTD | +34.59% |
| Year | -83.58% |
| 3 Years | -99.70% |
| 5 Years | -99.88% |
| 10 Years | -99.82% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $1.79 | 157,700 |
| 2026-06-16 | $1.78 | 94,400 |
| 2026-06-15 | $1.66 | 52,700 |
| 2026-06-12 | $1.63 | 40,700 |
| 2026-06-11 | $1.66 | 59,200 |
| 2026-06-10 | $1.63 | 77,200 |
| 2026-06-09 | $1.67 | 69,400 |
| 2026-06-08 | $1.67 | 124,300 |
| 2026-06-05 | $1.60 | 143,200 |
| 2026-06-04 | $1.72 | 206,700 |
| 2026-06-03 | $1.65 | 150,300 |
| 2026-06-02 | $1.70 | 240,200 |
| 2026-06-01 | $1.49 | 181,100 |
| 2026-05-29 | $1.42 | 33,300 |
| 2026-05-28 | $1.44 | 182,200 |
| 2026-05-27 | $1.48 | 114,200 |
| 2026-05-26 | $1.44 | 202,300 |
| 2026-05-22 | $1.52 | 63,100 |
| 2026-05-21 | $1.48 | 107,600 |
| 2026-05-20 | $1.35 | 19,700 |
| 2026-05-19 | $1.31 | 42,300 |
| 2026-05-18 | $1.36 | 70,900 |
About BioVie Inc.
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
đ° Latest News
BioVie: Long COVID trial fully enrolled â ICYMI
Proactive âĸ 2026-05-29T20:30:00Z
BioVie completes enrollment in Long COVID trial as need for treatments grows
Proactive âĸ 2026-05-26T17:34:17Z
BioVie completes enrollment in Phase 2 Long COVID trial
Proactive âĸ 2026-05-26T13:12:00Z
BioVie completes final patient visit in Parkinson's drug trial
Proactive âĸ 2026-05-19T12:31:00Z
BioVie CEO shares insights into long COVID trial - ICYMI
Proactive âĸ 2026-05-09T13:00:00Z
BioVie advances long COVID trial, top-line data expected by summer
Proactive âĸ 2026-05-04T15:24:56Z
BioVie abstract on Parkinsonâs drug accepted for neurology conference
Proactive âĸ 2026-04-14T09:10:00Z
BioVie CEO explains Bezisterim Parkinsonâs trial results - ICYMI
Proactive âĸ 2026-04-11T11:27:00Z
BioVie targets neuroinflammation and insulin resistance in Parkinsonâs treatment approach
Proactive âĸ 2026-04-09T17:44:57Z
BioVie targets Parkinsonâs at its source with lead drug bezisterim
Proactive âĸ 2026-03-26T15:00:03Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $332,720 | $2,893,922 | $4,300,150 | $2,162,989 |
| Total Expenses | $18,066,200 | $32,179,585 | $45,080,448 | $27,252,977 |
| Other Income Expense | $3,771 | $1,816,271 | $-1,437,481 | $3,287,418 |
| Net Non Operating Interest Income Expense | $520,309 | $-1,757,219 | $-3,737,886 | $-2,118,909 |
| Interest Expense Non Operating | $332,720 | $2,893,922 | $4,300,150 | $2,162,989 |
| Operating Expense | $18,066,200 | $32,179,585 | $45,080,448 | $27,252,977 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-17,542,120 | $-32,120,533 | $-50,255,815 | $-26,084,468 |
| Net Interest Income | $520,309 | $-1,757,219 | $-3,737,886 | $-2,118,909 |
| Interest Income | $853,029 | $1,136,703 | $562,264 | $44,080 |
| Normalized Income | $-17,545,891 | $-33,936,804 | $-48,818,334 | $-29,371,886 |
| Net Income From Continuing And Discontinued Operation | $-17,542,120 | $-32,120,533 | $-50,255,815 | $-26,084,468 |
| Total Operating Income As Reported | $-18,066,200 | $-32,179,585 | $-45,080,448 | $-27,252,977 |
| Net Income Common Stockholders | $-17,911,585 | $-33,006,956 | $-50,255,815 | $-26,084,468 |
| Net Income | $-17,542,120 | $-32,120,533 | $-50,255,815 | $-26,084,468 |
| Net Income Including Noncontrolling Interests | $-17,542,120 | $-32,120,533 | $-50,255,815 | $-26,084,468 |
| Net Income Continuous Operations | $-17,542,120 | $-32,120,533 | $-50,255,815 | $-26,084,468 |
| Pretax Income | $-17,542,120 | $-32,120,533 | $-50,255,815 | $-26,084,468 |
| Interest Income Non Operating | $853,029 | $1,136,703 | $562,264 | $44,080 |
| Operating Income | $-18,066,200 | $-32,179,585 | $-45,080,448 | $-27,252,977 |
| Depreciation Amortization Depletion Income Statement | $229,377 | $229,377 | $229,377 | $229,377 |
| Depreciation And Amortization In Income Statement | $229,377 | $229,377 | $229,377 | $229,377 |
| Amortization Of Intangibles Income Statement | $229,377 | $229,377 | $229,377 | $229,377 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-12.12 | $-73.05 | $-154.70 | $-106.00 |
| Basic EPS | $-12.12 | $-73.05 | $-154.70 | $-106.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-16,983,794 | $-30,813,505 | $-44,288,807 | $-26,979,520 |
| Total Unusual Items | $3,771 | $1,816,271 | $-1,437,481 | $3,287,418 |
| Total Unusual Items Excluding Goodwill | $3,771 | $1,816,271 | $-1,437,481 | $3,287,418 |
| Reconciled Depreciation | $229,377 | $229,377 | $229,377 | $229,377 |
| EBITDA (Bullshit earnings) | $-16,980,023 | $-28,997,234 | $-45,726,288 | $-23,692,102 |
| EBIT | $-17,209,400 | $-29,226,611 | $-45,955,665 | $-23,921,479 |
| Diluted Average Shares | $1,477,372 | $451,853 | $324,834 | $246,625 |
| Basic Average Shares | $1,477,372 | $451,853 | $324,834 | $246,625 |
| Diluted NI Availto Com Stockholders | $-17,911,585 | $-33,006,956 | $-50,255,815 | $-26,084,468 |
| Otherunder Preferred Stock Dividend | $369,465 | $886,423 | $0 | $0 |
| Gain On Sale Of Security | $3,771 | $1,816,271 | $-1,437,481 | $3,287,418 |
| Amortization | $229,377 | $229,377 | $229,377 | $229,377 |
| Research And Development | $9,266,734 | $23,100,394 | $33,299,503 | $17,258,341 |
| Selling General And Administration | $8,570,089 | $8,849,814 | $11,551,568 | $9,765,259 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $18,487,933 | $14,752,786 | $14,357,480 | $2,458,752 |
| Total Assets | $21,562,199 | $25,208,345 | $35,104,730 | $20,114,594 |
| Total Non Current Assets | $863,705 | $1,160,155 | $1,063,595 | $1,334,999 |
| Goodwill And Other Intangible Assets | $524,052 | $753,429 | $982,806 | $1,212,183 |
| Other Intangible Assets | $178,341 | $407,718 | $637,095 | $866,472 |
| Current Assets | $20,698,494 | $24,048,190 | $34,041,135 | $18,779,595 |
| Other Current Assets | $1,049,897 | $204,392 | $102,526 | $137,879 |
| Receivables | $2,104,050 | $0 | - | - |
| Other Receivables | $2,104,050 | - | - | - |
| Cash Cash Equivalents And Short Term Investments | $17,544,547 | $23,843,798 | $33,938,609 | $18,641,716 |
| Cash And Cash Equivalents | $17,544,547 | $23,843,798 | $19,460,883 | $18,641,716 |
| Cash Equivalents | $13,566,276 | $11,079,857 | $13,156,340 | - |
| Cash Financial | $3,978,271 | $12,763,941 | $6,304,543 | $18,641,716 |
| Other Non Current Assets | - | - | - | $4,562 |
| Prepaid Assets | - | - | - | $137,879 |
| Debt | ||||
| Total Debt | $349,894 | $6,111,447 | $14,419,758 | $12,264,984 |
| Long Term Debt And Capital Lease Obligation | $275,430 | $349,894 | $5,269,775 | $12,226,100 |
| Current Debt And Capital Lease Obligation | $74,464 | $5,761,553 | $9,149,983 | $38,884 |
| Current Debt | - | $5,701,210 | $9,105,074 | - |
| Other Current Borrowings | - | $5,701,210 | $9,105,074 | - |
| Long Term Debt | - | - | $5,227,270 | $12,138,686 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,550,214 | $9,702,130 | $19,764,444 | $16,443,659 |
| Total Non Current Liabilities Net Minority Interest | $275,430 | $349,894 | $5,269,775 | $12,274,485 |
| Current Liabilities | $2,274,784 | $9,352,236 | $14,494,669 | $4,169,174 |
| Payables And Accrued Expenses | $2,200,320 | $3,586,912 | $3,476,259 | $2,442,804 |
| Other Current Liabilities | - | $3,771 | $1,868,427 | $1,687,486 |
| Other Non Current Liabilities | - | - | - | $48,385 |
| Equity | ||||
| Common Stock Equity | $19,011,985 | $15,506,215 | $15,340,286 | $3,670,935 |
| Total Equity Gross Minority Interest | $19,011,985 | $15,506,215 | $15,340,286 | $3,670,935 |
| Stockholders Equity | $19,011,985 | $15,506,215 | $15,340,286 | $3,670,935 |
| Retained Earnings | $-352,144,246 | $-334,232,661 | $-301,225,705 | $-250,969,890 |
| Gains Losses Not Affecting Retained Earnings | - | $0 | $176,591 | - |
| Other Equity Adjustments | - | - | $176,591 | - |
| Other | ||||
| Treasury Shares Number | $2,837 | $2,632 | $228 | - |
| Ordinary Shares Number | $1,914,224 | $619,007 | $364,289 | $249,840 |
| Share Issued | $1,917,061 | $621,639 | $364,517 | $249,840 |
| Tangible Book Value | $18,487,933 | $14,752,786 | $14,357,480 | $2,458,752 |
| Invested Capital | $19,011,985 | $21,207,425 | $29,672,630 | $15,809,621 |
| Working Capital | $18,423,710 | $14,695,954 | $19,546,466 | $14,610,421 |
| Capital Lease Obligations | $349,894 | $410,237 | $87,414 | $126,298 |
| Total Capitalization | $19,011,985 | $15,506,215 | $20,567,556 | $15,809,621 |
| Treasury Stock | $29 | $27 | $2 | $0 |
| Additional Paid In Capital | $371,148,784 | $349,732,674 | $316,385,759 | $254,638,329 |
| Capital Stock | $7,476 | $6,229 | $3,643 | $2,496 |
| Common Stock | $7,476 | $6,229 | $3,643 | $2,496 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $275,430 | $349,894 | $42,505 | $87,414 |
| Current Capital Lease Obligation | $74,464 | $60,343 | $44,909 | $38,884 |
| Goodwill | $345,711 | $345,711 | $345,711 | $345,711 |
| Net PPE | $339,653 | $406,726 | $80,789 | $118,254 |
| Gross PPE | $339,653 | $406,726 | $80,789 | $118,254 |
| Buildings And Improvements | $339,653 | $406,726 | $80,789 | $118,254 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | - | $0 | $14,477,726 | $0 |
| Other Properties | - | - | $80,789 | $118,254 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-19,025,205 | $-27,945,024 | $-40,252,881 | $-18,990,850 |
| Operating Activities | ||||
| Operating Cash Flow | $-19,025,205 | $-27,945,024 | $-40,252,881 | $-18,990,850 |
| Cash Flow From Continuing Operating Activities | $-19,025,205 | $-27,945,024 | $-40,252,881 | $-18,990,850 |
| Operating Gains Losses | $-3,771 | $-2,040,136 | $1,437,481 | $-3,287,418 |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $14,525,000 | $-14,301,135 | $0 |
| Cash Flow From Continuing Investing Activities | $0 | $14,525,000 | $-14,301,135 | $0 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $15,674,613 | $27,802,939 | $55,370,943 | $18,511,009 |
| Financing Cash Flow | $12,725,954 | $17,802,939 | $55,373,183 | $33,120,924 |
| Cash Flow From Continuing Financing Activities | $12,725,954 | $17,802,939 | $55,373,183 | $33,120,924 |
| Net Common Stock Issuance | $15,674,613 | $27,802,939 | $55,370,943 | $18,511,009 |
| Common Stock Issuance | $15,674,613 | $27,802,939 | $55,370,943 | $18,511,009 |
| Other | ||||
| Repayment Of Debt | $-5,850,000 | $0 | $0 | $0 |
| Interest Paid Supplemental Data | $183,930 | $1,525,056 | $2,106,491 | $964,241 |
| End Cash Position | $17,544,547 | $23,843,798 | $19,460,883 | $18,641,716 |
| Beginning Cash Position | $23,843,798 | $19,460,883 | $18,641,716 | $4,511,642 |
| Changes In Cash | $-6,299,251 | $4,382,915 | $819,167 | $14,130,074 |
| Proceeds From Stock Option Exercised | $2,901,341 | $-10,000,000 | $2,240 | $0 |
| Net Issuance Payments Of Debt | $-5,850,000 | $0 | $0 | $14,609,915 |
| Net Short Term Debt Issuance | $-5,850,000 | $0 | - | $14,609,915 |
| Short Term Debt Payments | $-5,850,000 | $0 | - | - |
| Net Investment Purchase And Sale | $0 | $14,525,000 | $-14,301,135 | $0 |
| Sale Of Investment | $0 | $14,525,000 | - | - |
| Change In Working Capital | $-4,396,490 | $-86,843 | $-270,439 | $2,750,786 |
| Change In Other Current Liabilities | $-60,343 | $-95,630 | $-1,343,809 | $1,353,310 |
| Change In Payables And Accrued Expense | $-1,386,592 | $110,653 | $1,033,455 | $1,446,430 |
| Change In Prepaid Assets | $-845,505 | $-101,866 | $39,915 | $-48,954 |
| Change In Receivables | $-2,104,050 | $0 | - | - |
| Other Non Cash Items | $215,863 | $1,412,997 | $2,231,123 | $1,206,794 |
| Stock Based Compensation | $2,471,936 | $4,660,114 | $6,375,392 | $6,194,079 |
| Depreciation Amortization Depletion | $229,377 | $229,377 | $229,377 | $229,377 |
| Depreciation And Amortization | $229,377 | $229,377 | $229,377 | $229,377 |
| Amortization Cash Flow | $229,377 | $229,377 | $229,377 | $229,377 |
| Amortization Of Intangibles | $229,377 | $229,377 | $229,377 | $229,377 |
| Gain Loss On Investment Securities | $-3,771 | $-2,040,136 | $1,437,481 | $-3,287,418 |
| Net Income From Continuing Operations | $-17,542,120 | $-32,120,533 | $-50,255,815 | $-26,084,468 |
| Net Long Term Debt Issuance | - | $-10,000,000 | $0 | $14,609,915 |
| Long Term Debt Payments | - | $-10,000,000 | $0 | $0 |
| Issuance Of Debt | - | - | $0 | $14,609,915 |
| Long Term Debt Issuance | - | - | $0 | $14,609,915 |
| Purchase Of Investment | - | - | $-14,301,135 | $0 |
| Income Tax Paid Supplemental Data | - | - | - | $0 |
| Short Term Debt Issuance | - | - | - | $14,609,915 |
| Change In Other Current Assets | - | - | - | $-48,954 |
Fetched: 2026-06-17